Kilpatrick GJ, McIntyre MS, Cox RF, Stafford JA, Pacofsky GJ, Lovell GG, et al. CNS 7056: a novel ultra-short-acting benzodiazepine. Anesthesiology. 2007;107(1):60–6.

Article  PubMed  CAS  Google Scholar 

Rang HP, Dale MM, Ritter JM, Flower RJ. Rang and Dale’s pharmacology. 6th ed. Philadelphia: Elsevier; 2007.

Google Scholar 

Antonik LJ, Goldwater DR, Kilpatrick GJ, Tilbrook GS, Borkett KM. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): part I. Safety, efficacy, and basic pharmacokinetics. Anesth Analg. 2012;115(2):274–83.

Article  PubMed  CAS  Google Scholar 

Kilpatrick GJ. Remimazolam: non-clinical and clinical profile of a new sedative/anesthetic Aaent. Front Pharmacol. 2021;12: 690875.

Article  PubMed  PubMed Central  CAS  Google Scholar 

US FDA. Byfavo® (remimazolam) for injection, for intravenous use, CIV Initial US Approval: 2020. 2023.

Masui K. Remimazolam besilate, a benzodiazepine, has been approved for general anesthesia! J Anesth. 2020;34(4):479–82.

Article  PubMed  Google Scholar 

European Medicines Agency. Byfavo. 2024. https://www.ema.europa.eu/en/medicines/human/EPAR/byfavo. Accessed 30 Oct 2024.

PLC C. EndNote 21™. 21.3 (Build 17918) ed. St. Helier, Sjersey: Clarivate™; 2024.

DrugBAnk Online. Remimazolam: uses, interactions, mechanism of action. 24 Aug 2024. https://go.drugbank.com/drugs/DB12404. Accessed 30 Oct 2024.

European Medicines Agency. EMA summary of product characteristics (SmPC) Byfavo (remimazolam). 6 May 2024. https://www.ema.europa.eu/en/documents/product-information/byfavo-epar-product-information_en.pdf. Accessed 11 Jun 2024.

MHRA. Public assessment report: national procedure: Byfavo 20mg powder for solution for injection remimazolam besylate PLGB 54212/0001. 2021. https://mhraproducts4853.blob.core.windows.net/docs/c71074a0d61f2f8f76ac9f046bee4b2b9e282899. Accessed 19 Nov 2024.

毅峰 Ngc-林. YPSN202300028-N2(PPT).pdf - 注射用甲苯磺酸瑞马唑仑 (瑞倍宁®). nhsa.gov.cn; 2023: p. 3. Accessed 13 Jul 2025.

Ltd JHPC. Hengrui pipeline: 恒瑞医药. https://www.hengrui.com/en/pipeline.html. Accessed 21 Aug 2024.

Zhang H, Fu M, Yue F, Wei Y, Shi X, Yu S, Ji F. Comparison of the anesthetic effects of remimazolam tosilate and remimazolam besylate in daytime hysteroscopic surgery. BMC Anesthesiol. 2024;24(1):382.

Article  PubMed  PubMed Central  CAS  Google Scholar 

MHRA. Summary of product characteristics. 30 Aug 2023. https://mhraproducts4853.blob.core.windows.net/docs/d33377f81962ea12047c7c8e7fa4657a3c189f16. Accessed 19 Nov 2024.

Fechner J, El-Boghdadly K, Spahn DR, Motsch J, Struys M, Duranteau O, et al. Anaesthetic efficacy and postinduction hypotension with remimazolam compared with propofol: a multicentre randomised controlled trial. Anaesthesia. 2024;79(4):410–22.

Article  PubMed  CAS  Google Scholar 

Doi M, Hirata N, Suzuki T, Morisaki H, Morimatsu H, Sakamoto A. Safety and efficacy of remimazolam in induction and maintenance of general anesthesia in high-risk surgical patients (ASA Class III): results of a multicenter, randomized, double-blind, parallel-group comparative trial. J Anesth. 2020;34(4):491–501.

Article  PubMed  Google Scholar 

Doi M, Morita K, Takeda J, Sakamoto A, Yamakage M, Suzuki T. Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial. J Anesth. 2020;34(4):543–53.

Article  PubMed  Google Scholar 

Kim WJ, Li J, Oh I-S, Song I, Lee E, Namkoong K, Shin J-Y. Benzodiazepine use and risk of acute angle-closure glaucoma: a population-based case-crossover study. Drug Saf. 2020;43(6):539–47.

Article  PubMed  CAS  Google Scholar 

Keam SJ. Remimazolam: first approval. Drugs. 2020;80(6):625–33.

Article  PubMed  Google Scholar 

Kempenaers S, Hansen TG, Van de Velde M. Remimazolam and serious adverse events: a scoping review. Eur J Anaesthesiol. 2023;40(11):841–53.

Article  PubMed  Google Scholar 

Volcheck GW, Mertes PM. Local and general anesthetics immediate hypersensitivity reactions. Immunol Allergy Clin N Am. 2014;34(3):525–46.

Article  Google Scholar 

Hu X, Tang Y, Fang X. Laryngeal edema following remimazolam-induced anaphylaxis: a rare clinical manifestation. BMC Anesthesiol. 2023;23(1):99.

Article  PubMed  PubMed Central  Google Scholar 

Pesic M, Schippers F, Saunders R, Webster L, Donsbach M, Stoehr T. Pharmacokinetics and pharmacodynamics of intranasal remimazolam—a randomized controlled clinical trial. Eur J Clin Pharmacol. 2020;76(11):1505–16.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Pesic M, Stöhr T, Ossig J, Borkett K, Donsbach M, Dao VA, et al. Remimazolam has low oral bioavailability and no potential for misuse in drug-facilitated sexual assaults, with or without alcohol: results from two randomised clinical trials. Drugs R D. 2020;20(3):267–77.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Schmalix W, Petersen KU, Pesic M, Stohr T. The metabolism of the new benzodiazepine remimazolam. Curr Drug Metab. 2024;25(2):164–73.

Article  PubMed  CAS  Google Scholar 

Zhou Y, Hu P, Jiang J. Metabolite characterization of a novel sedative drug, remimazolam in human plasma and urine using ultra high-performance liquid chromatography coupled with synapt high-definition mass spectrometry. J Pharm Biomed Anal. 2017;15(137):78–83.

Article  Google Scholar 

Stöhr T, Colin PJ, Ossig J, Pesic M, Borkett K, Winkle P, et al. Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment. Br J Anaesth. 2021;127(3):415–23.

Article  PubMed  Google Scholar 

Petersen KU, Schmalix W, Pesic M, Stohr T. Drug-drug interaction potential of remimazolam: CYP 450, transporters, and protein binding. Curr Drug Metab. 2024;25(4):266–75.

Article  PubMed  CAS  Google Scholar 

Schüttler J, Eisenried A, Lerch M, Fechner J, Jeleazcov C, Ihmsen H. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: part I. Pharmacokinetics and clinical pharmacodynamics. Anesthesiology. 2020;132(4):636–51.

Article  PubMed  Google Scholar 

Wiltshire HR, Kilpatrick GJ, Tilbrook GS, Borkett KM. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. Anesth Analg. 2012;115(2):284–96.

Article  PubMed  CAS  Google Scholar 

Zhou J, Leonowens C, Ivaturi VD, Lohmer LL, Curd L, Ossig J, et al. Population pharmacokinetic/pharmacodynamic modeling for remimazolam in the induction and maintenance of general anesthesia in healthy subjects and in surgical subjects. J Clin Anesth. 2020;66: 109899.

Article  PubMed  CAS  Google Scholar 

Zhou J, Curd L, Lohmer LL, Ossig J, Schippers F, Stoehr T, et al. Population Pharmacokinetics of remimazolam in procedural sedation with nonhomogeneously mixed arterial and venous concentrations. Clin Transl Sci. 2021;14(1):326–34.

Article  PubMed  CAS  Google Scholar 

Masui K, Stöhr T, Pesic M, Tonai T. A population pharmacokinetic model of remimazolam for general anesthesia and consideration of remimazolam dose in clinical practice. J Anesth. 2022;36(4):493–505.

Article  PubMed  Google Scholar 

Eleveld DJ, Colin PJ, van den Berg JP, Koomen JV, Stoehr T, Struys MMRF. Covariate analysis of remimazolam pharmacokinetics and pharmacodynamics and proposed dosing and concentrations for anaesthesia and sedation. Br J Anaesth. 2025;135:206–217.

Masui K, Hagihira S. Equilibration rate constant, k(e0), to determine effect-site concentration for the Masui remimazolam population pharmacokinetic model in general anesthesia patients. J Anesth. 2022;36(6):757–62.

Article  PubMed  Google Scholar 

Masui K, Hagihira S. Correction: equilibration rate constant, k(e0), to determine effect-site concentration for the Masui remimazolam population pharmacokinetic model in general anesthesia patients. J Anesth. 2022;36(6):763.

Article  PubMed  Google Scholar 

Vellinga R, Koomen JV, Eleveld DJ, Stöhr T, Pesic M, Struys M, et al. Target-controlled infusion of remimazolam in healthy volunteers shows some acute tolerance. Anesthesiology. 2024;140(2):207–19.

Article  PubMed  CAS  Google Scholar 

Eisenried A, Schüttler J, Lerch M, Ihmsen H, Jeleazcov C. Pharmacokinetics and pharmacodynamics of remimazolam (CNS 7056) after continuous infusion in healthy male volunteers: part II. Pharmacodynamics of electroencephalogram effects. Anesthesiology. 2020;132(4):652–66.

Article  PubMed  CAS  Google Scholar 

Vellinga R, Koomen JV, Eleveld DJ, Stohr T, Pesic M, Struys M, et al. Influence of remifentanil